Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
aripiprazole
ARIPiprazole
- Formulary Psychiatric Drug Formulary
- Formulary Miscellaneous Program Formulary
- Restricted Aristada and Aristada Initio --> 1,064 mg and 675 mg are restricted to use by psychiatrists (or with a psychiatrist consult) and initiation of therapy (or re-initiation of therapy if patient has been off drug for several weeks).
- Restricted Abilify --> oral solution is restricted to pediatrics.
- Non-formulary
- Therapeutic Interchange
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Abilify Maintena | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 300 mg | ||||
| Abilify Maintena | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 400 mg | ||||
| Abilify | SOLUTION, INTRAMUSCULAR | 9.75 mg/1.3 mL | ||||
| Abilify | SOLUTION, ORAL | 1 mg/ mL | ||||
| Aristada | SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR | 1,064 mg | ||||
| Aristada | SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR | 441 mg, 662 mg | ||||
| Aristada Initio | SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR | 675 mg/2.4 mL | ||||
| Aristada | SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR | 882 mg | ||||
| Abilify Discmelt | TABLET, DISINTEGRATING, ORAL | 10 mg, 15 mg, 20 mg, 30 mg | ||||
| Abilify | TABLET, ORAL | 2 mg, 5 mg, 10 mg, 15 mg | ||||
| Abilify MyCite | TABLET, ORAL | 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg |
Last updated: Jul. 1, 2024
- Black Box Warning: Elderly patients with dementia related psychosis
- Formulary, Not Routinely Stocked: Abilify --> 1 mg/ mL oral solution
The drug replacement program for Aristada and Aristada Initio is currently ON HOLD. We are unable to order replacement doses at this time. (July 1, 2024)
For Abilify Maintena, Aristada or Aristada Initio, please complete corresponding Access sample log found on the Pharmacy Shared Drive (S:Access\CentralPharm\Sample Drug Dispensing Log) prior to dispensing.
Example of Sample Log Databases
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
Notes
ARIPiprazole (Abilify Discmelt)
ARIPiprazole (Abilify)
OR
OLANZapine (ZyPREXA Zydis)
Automatically interchange Abilify Discmelt to Abilify IR tablets, unless ODT necessary, then interchange to olanzapine ODT.
ARIPiprazole lauroxil (Aristada)
ARIPiprazole ER inj. (Abilify Maintena)
ARIPiprazole with sensors (Abilify MyCite)
ARIPiprazole
Abilify medication guide
Abilify Maintena medication guide
Aristada medication guide
Abilify Maintena is classified as formulary, restricted to the 400 mg vial under Otsuka's institutional free drug program. Prepare 300 mg dose from 400 mg vial if needed. Protocol for use available. Pharmacist consult for drug interactions. If sample is dispensed, it MUST be logged in the Sample Log Database, and drug stock should be checked.
ABILIFY MAINTENA Pharmacist Consult
Aristada 441 mg, 662 mg, and 882 mg are classified as non-formulary, not stocked. Interchange dosages of 441 mg to Abilify Maintena 300 mg and doses of 662 mg to Abilify Maintena 400 mg (use required protocol). Aristada Initio 675 mg and Aristada 1,064 mg is restricted to use by psychiatrists (or with a psychiatrist consult) and initiation of therapy (or re-initiation of therapy if patient has been off drug for several weeks).
If Aristada 882 mg is ordered, contact prescriber to discuss use of Abilify Maintena 400 mg (qmonth injection) +/- oral supplementation or suggest deferring to outpatient setting.
Abilify ODT are classified as non-formulary, not stocked. If an ODT form is not essential, it should be automatically interchanged to regular aripiprazole tablets at the same dose. If an ODT form is desired, it should be interchanged to ZyPREXA Zydis: Abilify ODT 10 mg interchanged to ZyPREXA ZYDIS 5 mg and Abilify ODT 15 mg interchanged to ZyPREXA Zydis 10 mg.
Abilify suspension is non-formulary. Call physician for alternative if patient doesn't have home supply available.
Abilify oral solutionis restricted to pediatrics.
Abilify MyCite is classified as non-formulary. Interchange Abilify MyCite to generic ARIPiprazole at same dosage.
Reviewed: January 23, 2007 (Abilify Injection)
Reviewed: May 28, 2013 and June 24, 2014 (Abilify Maintena)
Reviewed: 15 December 2015 (Aristada)
Reviewed: November 14, 2006 (Abilify Discmelts)
Reviewed: September 28, 2005 (Abilify Suspension)
Reviewed: 24 July 2018 (Aristada 1,064 mg)
Reviewed: 25 Sept 2018 (Aristada Initio)
Reviewed: 18 Dec 18 (Abilify oral solution)
Reviewed: 20 Feb, 2020 (Abilify MyCite)
Updated: June 15, 2015 (Abilify IR IM 9.75 mg/1.3 mL - Discontinued)